Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report.

Ziąbska H, Kobayashi A, Karliński M

Case reports in neurological medicine28 Aug 2026Cited by 1 (Europe PMC)

PMID42666484PMCIDPMC13522924DOI10.1155/crnm/9962315PepBankPUB-42666484

Summary

Despite high recanalization rates with mechanical thrombectomy (MT), large-vessel occlusion stroke results in death or dependency in over half of patients. Cerebrolysin, a multimodal neuropeptide preparation, may attenuate ischemia-reperfusion injury and support early neurorehabilitation. We report a 88-year-old woman with moderate prestroke disability who presented 2 h after the onset of right hemiparesis and aphasia due to M2 occlusion of the left middle cerebral artery. She received intravenous tenecteplase followed by MT, achieving complete reperfusion after three passes with no direct complications and no immediate clinical improvement. Directly postprocedure, cerebrolysin 30 mL/day was initiated as adjunctive treatment. Over the next 24 h, neurological deficits gradually resolved with no hemorrhagic transformation or evident infarct on follow-up CT. As the patient did not require early intensive rehabilitation and regained her prestroke functional status, cerebrolysin was discontinued after three doses. This report is not intended to establish the therapeutic efficacy of short-course adjunctive cerebrolysin. It illustrates how clinical signals from randomized and observational studies can be interpreted for the purpose of individual therapeutic decisions.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome
In a woman with stroke, neurological deficits resolved after tenecteplase, thrombectomy, and adjunctive Cerebrolysin.
In plain wordsIn a woman with stroke, neurological deficits resolved after tenecteplase, thrombectomy, and adjunctive Cerebrolysin.
Peptide
Cerebrolysin
Outcome
DecreaseNeurological deficits
Study
n = 1
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Over the next 24 h, neurological deficits gradually resolved with no hemorrhagic transformation or evident infarct on follow-up CT.
1 context sentence(design, population, supporting numbers)
Summary · context
Directly postprocedure, cerebrolysin 30 mL/day was initiated as adjunctive treatment.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-4266648401
02HumanNot a test of Cerebrolysin aloneCase report or seriesSafety outcome
In a woman with stroke, no hemorrhagic transformation occurred after tenecteplase, thrombectomy, and adjunctive Cerebrolysin.
In plain wordsIn a woman with stroke, no hemorrhagic transformation occurred after tenecteplase, thrombectomy, and adjunctive Cerebrolysin.
Peptide
Cerebrolysin
Outcome
Not applicableHemorrhagic transformation
Study
n = 1
Outcome group
Adverse events · Nervous system and cognition
Source sentences
Summary
Over the next 24 h, neurological deficits gradually resolved with no hemorrhagic transformation or evident infarct on follow-up CT.
1 context sentence(design, population, supporting numbers)
Summary · context
Directly postprocedure, cerebrolysin 30 mL/day was initiated as adjunctive treatment.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-4266648402
03HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome
In a woman with stroke, follow-up CT showed no evident infarct after tenecteplase, thrombectomy, and adjunctive Cerebrolysin.
In plain wordsIn a woman with stroke, follow-up CT showed no evident infarct after tenecteplase, thrombectomy, and adjunctive Cerebrolysin.
Peptide
Cerebrolysin
Outcome
Not applicableInfarct on CT
Study
n = 1
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Over the next 24 h, neurological deficits gradually resolved with no hemorrhagic transformation or evident infarct on follow-up CT.
1 context sentence(design, population, supporting numbers)
Summary · context
Directly postprocedure, cerebrolysin 30 mL/day was initiated as adjunctive treatment.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-4266648403
04HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome
In a woman with stroke, prestroke function returned after tenecteplase, thrombectomy, and adjunctive Cerebrolysin, without early intensive rehabilitation.
In plain wordsIn a woman with stroke, prestroke function returned after tenecteplase, thrombectomy, and adjunctive Cerebrolysin, without early intensive rehabilitation.
Peptide
Cerebrolysin
Outcome
IncreasePrestroke functional status
Study
n = 1
Outcome group
Exercise and physical function · Nervous system and cognition
Source sentences
Summary
As the patient did not require early intensive rehabilitation and regained her prestroke functional status, cerebrolysin was discontinued after three doses.
1 context sentence(design, population, supporting numbers)
Summary · context
Directly postprocedure, cerebrolysin 30 mL/day was initiated as adjunctive treatment.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-4266648404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.